On targetplus cd36 sirna

miR mimic and siRNA were transfected using HiPerfect (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Overexpression of miR-200c in primary human MΦ was performed in 6-well plates using MISSION^® hsa-miR-200c-3p mimic or MISSION^® miR negative control 2 (cel-miR-39a; both from Sigma-Aldrich). To block NRP1/2 or CD36 gene expression, MΦ were transfected with ON-TARGETplus NRP1/2 siRNA, ON-TARGETplus CD36 siRNA, or control siRNA (all from Dharmacon, Lafayette, CO, USA).

Both miR mimic and siRNA transfection were performed using HiPerfect (Qiagen) according to the manufacturer’s instructions. For overexpression of miR-375 primary human MΦ in six-well plates were transfected with MISSION^® hsa-miR-375 mimic or MISSION^® miR negative control 2 from C. elegans (cel-miR-39a; both from Sigma-Aldrich). De novo synthesis of mature miRs in MΦ upon coculture was prevented using DICER siRNA or control siRNA (Santa Cruz biotechnology). To block CD36 gene expression, MΦ were transfected with ON-TARGETplus CD36 siRNA or control siRNA (both from Dharmacon, Lafayette, Colorado, USA). Double KD of PXN and TNS3 was performed in primary human MΦ using PXN/TNS3 siRNA or control siRNA (Santa Cruz biotechnology). To interfere with the binding of miR-375 to its targets, miRCURY LNA^TM miRNA Power Target Site Blockers (Qiagen) with the following custom sequences were used according to the manufacturer’s instructions: PXN 5′-CTGTCCATCCCGCACCAGCG-3′, TNS3 5′-CTCGCCCAGCTCGCCCA-3′, and scramble control 5′-ACGTCTATACGCCCA-3′.